# Non-Viral Nanovectors Based on Cyclodextrins for siRNA Delivery: An Update to Current Technologies

## TL;DR

This paper reviews recent advances in using cyclodextrin-based nanovectors for delivering siRNA, highlighting their potential as safe and effective non-viral delivery systems.

## Contribution

The paper provides a comprehensive overview of recent developments in cyclodextrin-based nanovectors for siRNA delivery, emphasizing structural and functional innovations.

## Key findings

- Cyclodextrin-based nanovectors show improved siRNA transfection and safety.
- Structural and chemical modifications of cyclodextrins influence encapsulation and release efficiency.
- These nanovectors are versatile and biocompatible, making them promising for therapeutic applications.

## Abstract

Gene delivery/administration and, in particular, small interfering RNA (siRNA) delivery represent a therapeutic challenge, though very effective carriers have yet to be identified. Cyclodextrins (CDs) are cyclic oligosaccharides with unique host–guest inclusion capabilities, widely recognized in the pharmaceutical field for their ability to enhance drug solubility and bioavailability. Their excellent biocompatibility and chemical versatility make them powerful building blocks for the design of supramolecular nanovectors (NVs). Thanks to their facility of functionalization, CDs are highly versatile and have found numerous applications across various fields. In this context, CD-based NVs are currently explored as non-viral agents to transport and release siRNA. Recent studies suggest that self-assembled NVs based on CDs can improve the transfection and safety of siRNA delivery. This review provides a comprehensive overview of the most recent advances in the design of NVs based on CDs and their use for siRNA delivery, discussing the role played by structural differences and chemical functionalization in the context of encapsulation and release.